Exhibit 99.1 Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights · Encouraging preliminary data announced from the NXP800 Phase 1b study in platinum resistant, ARID1a-mutated ovarian cancer, a program granted Fast Track Designation by the US FDA · Data presented at the 2024 AACR demonstrate NXP900's robust activity in non-small cell cancer cell lines · Several clinical data updates expected in 2H 2024 May 7, 2024, Fort Lee, NJ - Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("N ...